Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

Understanding the fundamental biological processes underlying normal and malignant haematopoiesis and translate this to improve patient outcomes through new rational therapies.


About the Research

The main focus of the laboratory is understand human haemopoiesis, both normal and leukaemic. Our work also uses mouse models when appropriate. We focus on purifying normal and leukaemic human stem and progenitor populations[1-3] as this is a required base to the molecular mechanisms of how different leukaemogenic mutations cause differentiation arrest. We also study the mechanistic basis of clonal response and resistance to novel anti-leukaemic therapy[4]. Our expertise is complex flow cytometry, single cell analysis of RNA, chromatin and mutational profile in normal and leukaemic cells. We have particular expertise in study of primary human cells. Finally, we are developing novel models to study niche function and the immune response to leukaemia.

The type of projects a candidate may work on include: (i) defining the heterogeneity of normal human stem cells by purifying the most potent stem cells and understanding if they have lineage bias (a collaborative project with Professor Claus Nerlov). We also study mechanisms involved in the differentiation of early normal haemopoietic progenitors and in this regard we are undertaking in vivo bar-coding and single cell systems approaches. We collaborate with the Nerlov and Gottgens laboratories on these projects. We have projects on transcriptional deregulation in acute myeloid leukaemia (some in collaboration with Professor Irene Roberts), clonal haemopoiesis and understanding the role of the niche in clonal haemopoiesis and in acute myeloid leukaemia. Much of the work is focussed on specific mechanistic questions.


Training Opportunities

The projects and laboratory will provide high quality training in stem/progenitor purification and cell biology, single cell analysis of RNA, chromatin and DNA, cancer biology (using leukaemia as a model) and immune responses in cancer. Successful applicants will develop transferable skills in bench science and computational biology (including coding), as well critical ability to evaluate scientific data and place that data in the context of a field. Presentational and writing skills are also highly valued. We have weekly laboratory meetings and a separate journal club.


Students will be enrolled on the MRC WIMM DPhil Course, which takes place in the autumn of their first year. Running over several days, this course helps students to develop basic research and presentation skills, as well as introducing them to a wide-range of scientific techniques and principles, ensuring that students have the opportunity to build a broad-based understanding of differing research methodologies.

Generic skills training is offered through the Medical Sciences Division's Skills Training Programme. This programme offers a comprehensive range of courses covering many important areas of researcher development: knowledge and intellectual abilities, personal effectiveness, research governance and organisation, and engagement, influence and impact. Students are actively encouraged to take advantage of the training opportunities available to them.

As well as the specific training detailed above, students will have access to a wide-range of seminars and training opportunities through the many research institutes and centres based in Oxford.

All MRC WIMM graduate students are encouraged to participate in the successful mentoring scheme of the Radcliffe Department of Medicine, which is the host department of the MRC WIMM. This mentoring scheme provides an additional possible channel for personal and professional development outside the regular supervisory framework. The RDM also holds an Athena SWAN Silver Award in recognition of our efforts to build a happy and rewarding environment where all staff and students are supported to achieve their full potential.



  1. Goardon, N., E. Marchi, A. Atzberger, L. Quek, A. Schuh, S. Soneji, P. Woll, A. Mead, K.A. Alford, R. Rout, S. Chaudhury, A. Gilkes, S. Knapper, K. Beldjord, S. Begum, S. Rose, N. Geddes, M. Griffiths, G. Standen, A. Sternberg, J. Cavenagh, H. Hunter, D. Bowen, S. Killick, L. Robinson, A. Price, E. Macintyre, P. Virgo, A. Burnett, C. Craddock, T. Enver, S.E. Jacobsen, C. Porcher, and P. Vyas, Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell, 2011. 19(1): p. 138-52.
  2. Quek, L., G.W. Otto, C. Garnett, L. Lhermitte, D. Karamitros, B. Stoilova, I.J. Lau, J. Doondeea, B. Usukhbayar, A. Kennedy, M. Metzner, N. Goardon, A. Ivey, C. Allen, R. Gale, B. Davies, A. Sternberg, S. Killick, H. Hunter, P. Cahalin, A. Price, A. Carr, M. Griffiths, P. Virgo, S. Mackinnon, D. Grimwade, S. Freeman, N. Russell, C. Craddock, A. Mead, A. Peniket, C. Porcher, and P. Vyas, Genetically distinct leukemic stem cells in human CD34- acute myeloid leukemia are arrested at a hemopoietic precursor-like stage. J Exp Med, 2016. 213(8): p. 1513-35.
  3. Karamitros, D., B. Stoilova, Z. Aboukhalil, F. Hamey, A. Reinisch, M. Samitsch, L. Quek, O. G., E. Repapi, J. Doondeea, B. Usukhbayar, J. Calvo, S. Taylor, N. Goardon, E. Six, F. Pflumio, C. Porcher, R. Majeti, B. Gottgens, and P. Vyas, Single-cell analysis reveals the continuum of human lympho-myeloid progenitor cells. Nature Immunology, 2018. 19: p. 85-97.
  4. Quek, L., M.D. David, A. Kennedy, M. Metzner, M. Amatangelo, A. Shih, B. Stoilova, C. Quivoron, M. Heiblig, C. Willekens, V. Saada, S. Alsafadi, M.S. Vijayabaskar, A. Peniket, O.A. Bernard, S. Agresta, K. Yen, K. MacBeth, E. Stein, G.S. Vassiliou, R. Levine, S. De Botton, A. Thakurta, V. Penard-Lacronique, and P. Vyas, Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib. Nat Med, 2018. 24(8): p. 1167-1177.


Other potential supervisors

Prof Irene Roberts
MRC Weatherall Institute of Molecular Medicine